FRI0428 THE JAK1-SELECTIVE INHIBITOR, FILGOTINIB, INHIBITS INFLAMMATION PATHWAYS OBSERVED IN AN IL23-INDUCED PSORIATIC ARTHRITIS MOUSE MODEL
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease, of unknown aetiology, associated to the development of several comorbidities such as atherosclerosis. Splicing is a post-transcriptional process involved in the RNA maturation. Recent studies have revealed that a pathological dysregulation of the splicing machinery or spliceosome is associated to several human diseases. Yet, the spliceosome alterations have not been described in AS.
Objectives: 1) To analyze whether dysregulation of the spliceosome is present in AS. 2) To evaluate the association between the alteration of this process and the clinical, inflammatory, oxidative, and atherogenic profiles present in this pathology. Methods: Fourteen AS patients and 14 healthy donors (HDs) were included in the study. Disease function and activity status were analyzed using the BASFI and BASDAI. The expression of selected components of the major-(n=12) and minor-spliceosome (n=4), and splicing factors (n=28) was evaluated in purified monocytes, lymphocytes and neutrophils from patients and HDs (n=14 each) by Fluidigm methodology. Oxidative stress, inflammation and atherogenesis were evaluated by flow cytometry and RT-PCR. Endothelial function was determined by the post occlusive hyperaemia test using Laser-Doppler. Results: Compared to HDs, a significant dysregulation in the expression of relevant splicing factors and spliceosome components was found in all the leukocyte subtypes from AS patients, being neutrophils which displayed higher number of altered molecules. Interestingly, a specific altered profile of major-and minor-spliceosome members, and splicing factors was observed when compared lymphocytes (U4, U6, NOVA1, RMB17), monocytes (PRP8, SF3B TV2, CELF4, ESRP2, RBM3, SAM68 TV1, SRSF10, TIA1) and neutrophils (U11, U2, U2AF2, U11, CA 150, ESRP1, PSF, PTB, SRM160).
